argenx SE

NasdaqGS:ARGX Stock Report

Market Cap: US$39.8b

argenx Management

Management criteria checks 3/4

argenx's CEO is Tim Van Hauwermeiren, appointed in Apr 2008, has a tenure of 16.75 years. total yearly compensation is $11.94M, comprised of 5.5% salary and 94.5% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth $9.94M. The average tenure of the management team and the board of directors is 2.9 years and 7.8 years respectively.

Key information

Tim Van Hauwermeiren

Chief executive officer

US$11.9m

Total compensation

CEO salary percentage5.5%
CEO tenure16.8yrs
CEO ownership0.02%
Management average tenure2.9yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)

Jan 23

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Oct 31

argenx: Myositis Data Could Add Billions In Value

Sep 25

Argenx: Strong Setup For Outperformance In 2025

Jun 28

argenx: Innovation Over Losses In Autoimmune Arena

May 07

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

Feb 01

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

Sep 21

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

Aug 11

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

Jul 28

argenx: A Very Good Start For Vyvgart

May 25

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

May 18

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

Mar 07

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

Dec 22

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Nov 30

argenx: R&D Day Goes Unnoticed

Aug 23

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

Jun 30

Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals

Jun 07

Argenx raises ~$1B in global offering

Feb 03

argenx to raise $750M in proposed global offering

Feb 01

argenx on target to file efgartigimod applications in Japan and Europe

Jan 08

argenx and Zai Lab collaborate for Efgartigimod in Greater China

Jan 06

Argenx inks $98M deal to secure accelared review status for efgartigimod

Nov 23

argenx (ARGX) Investor Presentation - Slideshow

Nov 18

CEO Compensation Analysis

How has Tim Van Hauwermeiren's remuneration changed compared to argenx's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$40m

Jun 30 2024n/an/a

-US$204m

Mar 31 2024n/an/a

-US$328m

Dec 31 2023US$12mUS$656k

-US$295m

Sep 30 2023n/an/a

-US$234m

Jun 30 2023n/an/a

-US$397m

Mar 31 2023n/an/a

-US$511m

Dec 31 2022US$8mUS$639k

-US$710m

Sep 30 2022n/an/a

-US$909m

Jun 30 2022n/an/a

-US$907m

Mar 31 2022n/an/a

-US$595m

Dec 31 2021US$7mUS$652k

-US$408m

Sep 30 2021n/an/a

-US$373m

Jun 30 2021n/an/a

-US$319m

Mar 31 2021n/an/a

-US$573m

Dec 31 2020US$9mUS$641k

-US$608m

Sep 30 2020n/an/a

-US$535m

Jun 30 2020n/an/a

-US$359m

Mar 31 2020n/an/a

-US$275m

Dec 31 2019US$7mUS$589k

-US$181m

Sep 30 2019n/an/a

-US$109m

Jun 30 2019n/an/a

-US$104m

Mar 31 2019n/an/a

-US$47m

Dec 31 2018US$5mUS$573k

-US$76m

Compensation vs Market: Tim's total compensation ($USD11.94M) is about average for companies of similar size in the US market ($USD12.67M).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.

CEO

Tim Van Hauwermeiren (52 yo)

16.8yrs

Tenure

US$11,944,835

Compensation

Mr. Timothy Van Hauwermeiren, also known as Tim, MSc, EMBA, serves as Independent Non-Executive Director of Lexeo Therapeutics, Inc since July 2024. He has been Independent Director at iTeos Therapeutics,...

Leadership Team

NamePositionTenureCompensationOwnership
Timothy Van Hauwermeiren
Co-Founder16.8yrsUS$11.94m0.025%
$ 9.9m
Karl Gubitz
Chief Financial Officer3.6yrsUS$4.76m0.0049%
$ 1.9m
Karen Massey
Chief Operating Officer1.8yrsUS$7.65mno data
Filip Borgions
VP & Global Head of Technical Operations2.8yrsno datano data
Peter Ulrichts
Chief Scientific Officer2yrsno data0.00085%
$ 338.4k
Beth DelGiacco
VP and Global Head of Corporate Communications & Investor Relations2.8yrsno datano data
Malini Moorthy
General Counsel2.9yrsno data0%
$ 0
Arjen Lemmen
Vice President of Corporate Development & Strategy5.6yrsno data0.0020%
$ 804.1k
Marc Schorpion
Global Head of Human Resources6.1yrsno datano data
Andria Wilk
Global Head of Quality5yrsno data0.00049%
$ 195.0k
Luc Truyen
Chief Medical Officer2.8yrsno data0.0027%
$ 1.1m

2.9yrs

Average Tenure

52yo

Average Age

Experienced Management: ARGX's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Timothy Van Hauwermeiren
Co-Founder10.5yrsUS$11.94m0.025%
$ 9.9m
J. deBethizy
Independent Vice-Chairman of the Board9.7yrsUS$482.23k0.0011%
$ 449.8k
Peter K. Verhaeghe
Independent Chairman of the Board10.5yrsUS$660.33k0.0028%
$ 1.1m
Anthony Rosenberg
Independent Non-Executive Director7.8yrsUS$476.82k0.0011%
$ 449.8k
James Daly
Independent Non-Executive Director6.7yrsUS$482.23k0.0011%
$ 449.8k
Pamela M. Klein
Independent Non-Executive Director8.8yrsUS$471.41k0.0011%
$ 449.8k
Hans de Haard
Member of Board Advisorsno datano datano data
David Lacey
Member of Board Advisorsno dataUS$622.58kno data
Steve Krognes
Independent Non-Executive Director1.9yrsUS$635.65k0.00021%
$ 83.6k
Camilla Sylvest
Independent Non-Executive Director2.3yrsUS$365.24k0.00085%
$ 338.4k
Robert Woods
Member of Board Advisors1.8yrsUS$656.08k0.0054%
$ 2.2m
Wim Parys
Member of Board Advisorsno datano datano data

7.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: ARGX's board of directors are considered experienced (7.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/27 05:12
End of Day Share Price 2025/01/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

argenx SE is covered by 49 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Charles Pitman-KingBarclays
Richard ParkesBNP Paribas Exane